Prescription Medicines
Rotodipin Tab. 5/5mg
- Product Category
- Antihypertension & dyslipidemia treatment
- Active Ingredients
- Rosuvastatin, amlodipine
- Appearance
- Orange round film-coated tablet
- Reimbursement Code
- 648105190
01 / 02
1. Composition and Strength : 1 tablet
- Active ingredients:
Rosuvastatin calcium (EP) ······ 5.2mg (5mg as rosuvastatin)
Amlodipine besylate (EP) ······ 6.944mg (5mg as amlodipine)
- Additives: light anhydrous silicic acid, di-mannitol, microcrystalline cellulose, magnesium stearate, Opadry Orange (03B630006), sodium starch glycolate, pregelatinized starch, crospovidone, magnesium carbonate, povidone
2. Effectiveness
This drug is only used in patients who need to take two drugs (amlodipine and rosuvastatin) simultaneously.
○ Amlodipine
1. Myocardial ischemia caused by hypertension, fixed occlusion of the coronary artery (stable angina), or vasospasm and vasoconstriction of the coronary vascular system (atypical angina)
2. Patients with coronary heart disease recently confirmed by angiography and who do not have heart failure or cardiac output less than 40%
- Reduces the risk of hospitalization due to angina pectoris
- Reduced risk of coronary artery revascularization
○ Rosuvastatin
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb): As an adjunct to diet therapy if it cannot be controlled with diet and exercise
2. Adjuvant to diet or other lipid-lowering therapy (e.g. LDL apheresis) for homozygous familial hypercholesterolemia
3. Delays the progression of atherosclerosis by lowering total cholesterol and LDL-cholesterol to target levels in patients with hypercholesterolemia.
4. Dietary supplement for patients with primary dysbetalipoproteinemia (type III)
5. Reduced risk of cardiovascular disease: Patients with no clinical evidence of coronary heart disease, but men over 50 years of age and women over 60 years of age, high sensitive C-reactive protein (hsCRP) of 2 mg/L or more, and at least one additional cardiovascular disease risk factor (e.g. high blood pressure, low HDL-cholesterol level, smoking, or family history of premature coronary heart disease, etc.)
- Reduced risk of stroke
- Reduced risk of myocardial infarction
- Reduced risk of arterial revascularization
3. Dosage and dosage
This drug is administered only to adults, and the dosage should be individualized for each patient based on the effectiveness and tolerability of each component of amlodipine/rosuvastatin.
○ Amlodipine
Adults: Amlodipine is administered orally at 5 mg once a day, and the dose can be increased up to 10 mg per day depending on the patient's response. Increase or decrease appropriately depending on symptoms.
○ Rosuvastatin
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbeta-lipoproteinemia (type III), and homozygous familial hypercholesterolemia.
Patients before and while taking this drug should eat a standard cholesterol-lowering diet, and this should be continued during the treatment period. You can take this medication at any time of the day, regardless of meals. The initial dose is 5 milligrams once a day, and if further LDL-cholesterol level reduction is required, the maintenance dose can be adjusted. The maintenance dose is 10 milligrams once a day, and most patients are adjusted to this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more depending on the LDL-cholesterol level, treatment goals, and patient response, and the dose can be increased up to 20 milligrams per day.
2. Elderly: No dosage adjustment is necessary.
3. Patients with renal failure: For patients with mild to moderate renal failure, there is no need to adjust the dose. Do not administer to patients with severe renal failure. Particular caution should be exercised when administering 20 mg of this drug to patients with moderate renal failure.
4. Patients with liver failure: There was no increase in systemic exposure to rosuvastatin in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score exceeding 9. This drug is not administered to patients with active liver disease.
5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of doses of 40 milligrams is contraindicated.
6. Patients prone to myopathy: The recommended initial dose for patients prone to myopathy is 5 milligrams. In some of these patients, administration of rosuvastatin at a dose of 40 mg is contraindicated.
If a patient is taking amlodipine and rosuvastatin in combination, they can switch to this drug (a combination drug with the same content of each active ingredient) for convenience of administration.
4. Precautions for use
1. Do not administer to the following patients
1) Patients with hypersensitivity to the components of this drug or other dihydropyridine drugs
2) When administering this drug to pregnant women or women who may be pregnant, women of childbearing age who do not use an appropriate method of contraception, or lactating women or women of childbearing age, administer this drug only when informed of the high possibility of not becoming pregnant and the potential risk to the fetus.
3) Patients with severe liver dysfunction
4) Patients with active liver disease, including persistent serum transaminase elevations of unknown cause or serum transaminase elevations exceeding 3 times the upper limit of normal.
5) Patients with severe aortic stenosis
6) Shock patients
7) Patients with myopathy
8) Patients taking cyclosporine concurrently
9) Patients with severe renal failure (creatinine clearance (CLcr) <30mL/min)
10) Rosuvastatin administration at a dose of 40 mg is contraindicated in patients prone to myopathy/rhabdomyolysis. These factors are as follows.
- Moderate renal impairment (creatinine clearance < 60ml/min)
- Hypothyroidism
- If you have a history or family history of genetic muscle disease
- If there is a history of muscle toxicity to other HMG-CoA converting enzyme or fibrate drugs
- alcoholism
- Situations in which plasma concentrations may increase
- Asian patient
- Concomitant administration of fibrate-based drugs
2. Administer with caution to the following patients.
1) Patients with severe low blood pressure
2) Patients with renal failure requiring dialysis
3) Elderly people
4) Patients with severe muscle atony or ocular muscle atony (cases of recurrence when administered the same or different types of statin drugs have been reported).
5) Like other HMG-CoA reductase inhibitors, rosuvastatin should be administered with caution to patients who consume excessive alcohol or have a history of liver disease. It is recommended that liver enzyme tests be performed repeatedly as clinically necessary before and after starting treatment with this drug. Patients with hypercholesterolemia secondary to hypothyroidism or nephrotic syndrome must treat the causative disease before taking this drug.
6) Similar to other HMG-CoA reductase inhibitors, effects on skeletal muscle, such as myalgia and myopathy, and rarely rhabdomyolysis, have been reported in patients receiving rosuvastatin. Immune-mediated necrotizing myopathy has been reported in patients taking or discontinuing statins, including rosuvastatin. Immune-mediated myopathy is clinically characterized by weakened proximal muscles and increased CK (creatine kinase) in the blood, and the symptoms persist even after discontinuation of treatment.
· As with other HMG-CoA reductase inhibitors, the risks and benefits of treatment should be considered in the following patients with factors predisposing to myopathy/rhabdomyolysis, and clinical monitoring is recommended. Treatment should not be started if the CK (creatine kinase) value is significantly increased from the baseline level (more than 5 times the upper limit of normal) before treatment.
- Patients with renal impairment
- Hypothyroidism
- If you have a history or family history of genetic muscle disease
- If there is a history of muscle toxicity to other HMG-CoA reductase inhibitors or fibrates.
- alcohol abuse
- Seniors over 70 years old
- Situations in which plasma concentrations may increase
- Concomitant administration of fibrate-based drugs
· During treatment, unexplained muscle pain, muscle weakness or cramps should be reported immediately, especially if associated with malaise or fever. In these patients, the CK level should be measured, and if the CK level is significantly elevated (more than 5 times the upper limit of normal) or if the muscle symptoms are severe and cause daily discomfort even if the CK level increases below 5 times the upper limit of normal, administration of this drug should be discontinued. Once symptoms resolve and CK levels return to normal, consideration should be given to restarting rosuvastatin or another HMG-CoA reductase inhibitor at the lowest dose with close monitoring. Routine monitoring of CK levels is not necessary in asymptomatic patients.
· Because it may make interpretation of the measurement results difficult, do not measure the CK value after intense exercise or when there are other causes that may increase the CK value. If the CK value increases significantly from baseline (more than 5 times the upper limit of normal), a confirmatory test should be performed within 5 to 7 days. Even when repeating the test, this drug should not be administered if the baseline CK value increases more than 5 times the upper limit of normal.
7) This drug should be discontinued in acute severe conditions that suggest worsening of myopathy or renal failure secondary to rhabdomyolysis (e.g., sepsis, hypotension, major surgery, wounds, severe metabolic/endocrine/electrolyte diseases, uncontrolled epileptic seizures).
8) In clinical trials, there was no evidence of increased effect on skeletal muscle in the small number of patients who received rosuvastatin alone and in combination with other drugs. However, in the case of other HMG-CoA reductase inhibitors, the frequency of myositis and myopathy increased in patients receiving concurrent treatment with fibric acid derivatives (including gemfibrozil), cyclosporine, nicotinic acid, azole antifungals, protease inhibitors, and macrolide antibiotics. Gemfibrozil increases the risk of myopathy when combined with HMG-CoA reductase inhibitors. Therefore, the combined use of this drug and gemfibrozil is not recommended. When administering this drug in combination with fibrates or niacin, the benefits and risks should be carefully evaluated. A dose of 40 milligrams of rosuvastatin is contraindicated when coadministered with fibrate-based drugs.
9) In patients taking high doses of rosuvastatin, especially 40 mg, proteinuria, mostly of tubular origin, detected by dipstick test was observed. This is usually transient and is not a predictor of acute or progressive renal failure. Renal function tests should be considered during the follow-up period for patients receiving rosuvastatin 40 mg.
10) According to the pharmacokinetics test of rosuvastatin, increased systemic exposure (median AUC and Cmax approximately 2-fold increase) was found in Asians compared to Caucasians, so this should be taken into consideration when determining dosage for Asians.
11) This medicine 5/5 and 20/5mg contain Yellow No. 5 (Sunset Yellow FCF), so administer with caution to patients who are hypersensitive to this ingredient or have a history of allergy.
3. Adverse reactions
○ Information collected from this medicine (combined medicine)
1) Clinical trials
The safety of this drug was evaluated in a clinical trial in which 105 patients with essential hypertension and dyslipidemia were administered this drug (rosuvastatin/amlodipine 20/10 mg) or rosuvastatin 20 mg or amlodipine 10 mg once daily for 8 weeks.
The adverse reactions reported in this clinical trial, regardless of causal relationship, are listed in Table 1.
※ <Table 1> Adverse reactions: See attached document
Among these, adverse drug reactions for which a causal relationship with the drug could not be ruled out were peripheral edema in 5.71% (2 people) of the drug-treated group, dizziness 2.78% (1 person) in the rosuvastatin-treated group, and headache 2.94% (1 person) in the amlodipine-treated group.
2) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 654 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 26.30% (172/654 people, 237 cases) regardless of causal relationship.
Among these, no serious adverse drug reactions for which a causal relationship cannot be ruled out were reported, and unexpected adverse drug reactions are listed in the table below according to their frequency of occurrence.
※ Table: Refer to attached document
○ Information collected from amlodipine
1) Amlodipine is well tolerated. In placebo-controlled clinical trials in patients with hypertension and angina, the most common adverse reactions were as follows:
Vascular disorders: flushing
Whole body: fatigue, swelling
Cardiovascular system: palpitations
Central and peripheral nervous system: dizziness, headache, drowsiness
Digestive system: abdominal pain, nausea
No clinically significant laboratory abnormalities related to this drug were observed in clinical trials.
2) Adverse reactions observed with relatively low frequency after marketing are as follows:
Systemic: weakness, malaise, pain, weight gain/loss
Vascular disorders: hypotension, vasculitis
Nervous system: hypertonia, hypoesthesia/dysesthesias, peripheral neuropathy, syncope, dysgeusia, tremor, extrapyramidal disorder.
Reproductive system: erectile dysfunction, gynecomastia
Digestive system: Changes in bowel habits, dry mouth, indigestion (gastritis), gingival thickening, pancreatitis, vomiting.
Metabolism/Nutrition: Hyperglycemia
Musculoskeletal system: joint pain, back pain, muscle cramps, muscle pain
Blood and lymphatic system disorders: leukopenia, thrombocytopenia
Mental: Insomnia, mood swings
Respiratory disorders: cough, dyspnea, rhinitis
Skin/Appendixes: Hair loss, hyperhidrosis, purpura, skin discoloration, urticaria, toxic epidermal necrolysis
Sensory system: sound in ears, visual abnormality
Urinary system: increased urination frequency, urinary disorders, enuresis
Hepatobiliary system: Hepatitis, jaundice, and elevated liver enzyme levels were reported very rarely, and most of these were related to cholestasis. Some cases that were severe enough to require hospitalization were reported to be related to the use of amlodipine, but in most cases, the causal relationship with amlodipine is unclear.
Rarely, allergic reactions including pruritus, rash, angioedema, and erythema multiforme have been reported.
3) As with other calcium channel inhibitors, the following adverse reactions were rarely reported, but it was not possible to distinguish whether they were caused by the underlying disease or the drug: myocardial infarction, arrhythmia (including bradycardia, ventricular tachycardia, and atrial fibrillation), and chest pain.
4) Other adverse reactions as follows were observed.
Cardiovascular system: Occasionally, a drop in blood pressure, sinoatrial or atrioventricular block, and rarely abdominal discomfort may occur.
Digestive system: Occasionally, abdominal pain, diarrhea, loose stools, and constipation may occur.
Skin: In rare cases, redness of the skin and petechial-papular rash may occur.
Others: Occasionally, headache, hot flashes, decreased glucose tolerance, and weakness may occur.
○ Information collected from rosuvastatin
1) Reported adverse reactions were generally mild and transient. Less than 4% of patients in the rosuvastatin treatment group discontinued the study due to adverse reactions.
The frequency of adverse reactions was classified as follows:
Common (>1/100, <1/10);
Uncommon (>1/1,000, <1/100);
Rare (>1/10,000, <1/1,000);
Very rare (<1/10,000).
Not known (cannot be estimated from available data)
※ Table: Refer to attached document
As with other HMG-CoA reductase inhibitors, adverse reactions tended to increase as the dose increased.
2) Effect on kidneys: Proteinuria, mostly of tubular origin, detected by dipstick test, was observed. The phenomenon of conversion of urine protein from negative or very small amounts to ++ or higher occurred in less than 1% of cases at 10 or 20 milligrams and in about 3% of cases at 40 milligrams. A slight increase in urine protein from negative or very small amounts to + was also observed at the 20 mg dose. Proteinuria decreased or disappeared spontaneously during treatment in most cases and is not a predictor of acute or progressive renal failure. Hematuria was observed in patients and clinical trial data administered rosuvastatin, but the frequency of occurrence was low.
3) Effects on the musculoskeletal system: Effects on the musculoskeletal system with or without acute renal failure (e.g., myalgia, myopathy (including myositis), rarely rhabdomyolysis, etc.) have been reported in patients treated with all doses of rosuvastatin (especially doses above 20 mg). In the patient group receiving rosuvastatin, creatinine kinase (CK) levels increased in a dose-dependent manner. In most cases, it was mild, asymptomatic, and transient. If creatinine kinase (CK) levels increase significantly (more than 5 times the upper normal limit), treatment should be temporarily discontinued.
4) Effects on the liver: As with other HMG-CoA reductase inhibitors, transaminase levels increased in a dose-dependent manner in a small number of patients receiving rosuvastatin. In most cases, it was mild, asymptomatic, and transient.
5) Overseas post-marketing experience
In addition to the above adverse reactions, the following adverse reactions were reported during post-marketing surveillance.
- Nervous system: Very rare polyneuropathy, amnesia, peripheral neuropathy (frequency unknown)
- Respiratory system and chest: cough, difficulty breathing (frequency unknown)
- Gastrointestinal system: Diarrhea (frequency unknown)
- Hematological disorders: Thrombocytopenia (frequency unknown)
- Hepatobiliary system: very rare, jaundice, hepatitis, rarely increased transaminases
- Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome (frequency unknown), drug reaction syndrome with increased eosinophils and systemic symptoms (DRESS) (frequency unknown)
- Musculoskeletal system: Rarely lupus-like syndrome, muscle rupture, very rarely arthralgia, immune-mediated necrotizing myopathy (frequency unknown)
- Kidney: Very rare hematuria
- Other: Edema (frequency unknown)
The following adverse reactions have been reported in relation to some statin drugs.
- Mental nervous system: depression, sleep disorders (including insomnia and nightmares) (frequency unknown)
- Respiratory system: Exceptional cases such as interstitial lung disease, especially during long-term administration
- Urogenital system: sexual dysfunction, gynecomastia (frequency unknown)
- Hepatobiliary system: Fatal and non-fatal liver failure
There have been rare reports of post-marketing cognitive impairment associated with statin use. (e.g. memory loss, forgetfulness, amnesia, memory impairment, confusion) Such cognitive impairment has been reported with all statin drugs. These reports are generally not serious and reversible after discontinuation of drug use, but there is variation in the time of symptom onset (1 day to several years) and symptom improvement (median 3 weeks). The induction or worsening of severe muscle atony or ocular muscle atony has been reported with the administration of statin drugs.
6) Domestic post-marketing survey results
As a result of a use result survey conducted on 3,081 people over 6 years for re-examination in Korea, the incidence of adverse events regardless of causal relationship was 10.06% (310 people, 415 cases), mainly headache 0.78% (24 people, 24 cases), dizziness 0.75% (23 people, 23 cases), and ALT increase 0.58% (18 people, 18 cases). 18 cases), chest pain, cough, and muscle pain were reported in 0.49% (15 people, 15 cases) respectively. Of these, 2.92% (90 people, 106 cases) of adverse drug reactions for which a causal relationship with rosuvastatin could not be ruled out.
The most reported adverse drug reactions were ALT increase at 0.55% (17 people, 17 cases), muscle pain at 0.42% (13 people, 13 cases), headache at 0.39% (12 people, 12 cases), CK increase at 0.29% (9 people, 9 cases), dizziness at 0.26% (8 people, 8 cases), constipation, and AST increase. 0.16% (5 people, 5 cases), asthenia and joint pain each at 0.13% (4 people, 4 cases), fatigue and numbness at 0.10% each (3 people, 3 cases), paresthesia, chest discomfort, nausea, abdominal pain, diarrhea, loss of appetite, abdominal distension, itching, liver function test abnormalities at 0.06% each (2 people, 2 cases), syncope, systemic pain, Muscle cramps, gout, and erectile dysfunction each occurred in 0.03% (1 person, 1 case). Among these, muscle pain and joint pain in one patient were serious adverse drug reactions, and unexpected adverse drug reactions that did not occur before marketing included joint pain in 0.13% (4 patients, 4 cases), fatigue and numbness in 0.10% each (3 patients, 3 cases), paresthesia, chest discomfort, loss of appetite, abdominal distension, and liver function test abnormalities in 0.06% each (2 patients, 2 cases), syncope, and Systemic pain, muscle spasms, gout, and erectile dysfunction occurred in 0.03% (1 person, 1 case) each, and one case of joint pain was reported as a serious and unexpected adverse drug reaction.
There were 98 adverse events voluntarily reported during the re-examination period, of which 2 cases of acute renal failure and 1 case each of oliguria, thrombocytopenia, and increased blood creatinine were reported as serious and unexpected adverse drug reactions.
4. General precautions
○ Amlodipine
1) Administration to heart failure patients: In the long-term, placebo-controlled trial (PRAISE-2) of amlodipine in New York Heart Association (NYHA) class III and IV heart failure patients without ischemic etiology, amlodipine was associated with an increase in reports of pulmonary edema despite no significant difference in the worsening rate of heart failure compared to placebo.
2) Administration to patients with liver dysfunction: Like all calcium antagonists, the half-life of amlodipine is prolonged in patients with liver dysfunction, and the recommended dosage for these patients has not been established. Therefore, administer with caution to these patients.
3) Because the plasma concentration half-life is long, a gradual blood pressure lowering effect appears even after discontinuation of administration. Therefore, when administering other antihypertensive drugs after discontinuation of administration, pay attention to the dosage and administration interval and administer carefully while observing the patient's condition.
4) Since the effect appears slowly, the effect cannot be expected for unstable angina pectoris that requires emergency treatment.
5) Effects on driving and using machines
Based on clinical experience with amlodipine, it does not appear to impair the ability to drive or use machines.
○ Rosuvastatin
1) Interstitial lung disease: Unusual cases such as interstitial lung disease have been reported with some statin drugs, especially during long-term administration. Presenting symptoms may include difficulty breathing, cough without phlegm, and general deterioration in health (fatigue, weight loss, and fever). If a patient is suspected of developing interstitial lung disease, statin drug treatment should be discontinued.
2) Post-marketing cases of fatal and non-fatal liver failure have been rarely reported in patients taking statin drugs, including rosuvastatin. If severe liver damage and/or hyperbilirubinemia or jaundice with clinical symptoms occurs while taking this drug, treatment should be discontinued immediately. Do not re-administer this drug if no other etiology is found.
3) An increase in HbA1c and fasting blood sugar levels was reported when administering HMG-CoA reductase inhibitors, including rosuvastatin.
4) Diabetes: Some evidence suggests that hyperglycemia, which requires appropriate diabetes treatment, may occur in some patients at high risk of developing diabetes in the future. However, the vascular risk reduction effect of statins exceeds these risks and therefore cannot be a reason to discontinue statin treatment. Patients at risk (fasting blood sugar 5.6-6.9 mmol/L, BMI > 30kg/m2, elevated triglyceride level, hypertension) should undergo clinical and laboratory monitoring according to treatment guidelines. In the JUPITER study, the total incidence of diabetes reported in patients with fasting blood sugar levels of 5.6 to 6.9 mmol/L was 2.8% in the rosuvastatin group and 2.3% in the placebo group.
5) Genetic polymorphism: Compared to SLCO1B1 c.521TT and ABCG2 c.421CC, genotypes of SLCO1B1 (OATP1B1) c.521CC or ABCG2 (BCRP) c.421AA were reported to be associated with increased exposure (AUC) of rosuvastatin. Although the safety and effectiveness of this drug according to genetic polymorphisms have not been established, the dose needs to be adjusted according to the patient's treatment response and tolerance.
6) Severe skin adverse reactions: Severe skin adverse reactions that can be life-threatening or fatal, such as Stevens-Johnson syndrome (SJS), increased eosinophilia, and drug reaction syndrome with systemic symptoms (DRESS), have been reported with rosuvastatin. When prescribing, patients should be counseled and closely monitored for symptoms and signs of severe skin reactions. If symptoms and signs suggestive of these skin reactions occur, this medication should be discontinued immediately and alternative treatment options should be considered.
If a patient develops a severe reaction such as Stevens-Johnson syndrome or drug reaction syndrome with eosinophilia and systemic symptoms due to the use of this drug, treatment with this drug should not be resumed at any time.
7) Severe muscle asthenia and ocular muscle atony: Rarely, statin drugs may cause or worsen severe muscle asthenia or ocular muscle atony. This drug should be used with caution in patients with these conditions. Administration should be discontinued if severe muscle atony or ocular muscle atony occurs or worsens.
5. Interaction
As a result of a drug interaction test conducted by administering 20 mg of rosuvastatin and 10 mg of amlodipine to healthy volunteers, the Cmax,ss of rosuvastatin increased by about 1.3 times and the AUCτ,ss increased by about 1.2 times.
Studies on drug interactions between other drugs and the rosuvastatin/amlodipine combination were not conducted, but studies on the individual drugs amlodipine and rosuvastatin were conducted as follows.
○ Amlodipine
1) Amlodipine is safe when used in combination with thiazide diuretics, alpha-blockers, beta-blockers, ACE inhibitors, long-acting nitrate agents, sublingual nitroglycerin tablets, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic agents.
2) Laboratory data using human plasma show that amlodipine does not affect the protein binding of digoxin, phenytoin, warfarin, and indomethacin.
3) Grapefruit juice: A single co-administration of 240 mL of grapefruit juice and 10 mg of amlodipine in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine. In this study, the impact of genetic polymorphisms in CYP3A4, the main metabolic pathway for amlodipine, was not evaluated. Therefore, co-administration of amlodipine with grapefruit or grapefruit juice may increase the blood pressure lowering effect in some patients due to increased bioavailability, so co-administration is not recommended.
4) Dantrolene (injection): In animal experiments where verapamil and dantrolene were administered through IV, fatal ventricular spasms were consistently observed. Simultaneous administration of amlodipine and dantrolene should be avoided.
5) Baclofen: As it increases the blood pressure lowering effect, administer with caution regarding blood pressure and dosage if necessary.
6) Clarithromycin: Clarithromycin is a cytochrome P3A4 inhibitor. The risk of hypotension is increased when clarithromycin is coadministered with this drug. It is recommended that patients be carefully observed when coadministering this drug and clarithromycin.
7) How other drugs affect amlodipine
(1) Cimetidine: When administered in combination with amlodipine, there was no effect on the pharmacokinetics of amlodipine.
(2) Aluminum/magnesium (antacid): When aluminum/magnesium antacid was coadministered with a single dose of amlodipine, there was no significant effect on the pharmacokinetics of amlodipine.
(3) Sildenafil: Administration of a single dose of 100 mg of sildenafil to patients with primary hypertension did not affect the pharmacokinetic parameters of amlodipine. When amlodipine and sildenafil are administered together, each drug exerts its own blood pressure lowering effect independently.
(4) Cytochrome P3A4 inhibitor: In elderly (69 to 87 years old) hypertensive patients, coadministration of 180 mg of diltiazem and 5 mg of amlodipine per day increased the systemic exposure of amlodipine by 57%. In healthy volunteers (18 to 43 years of age) co-administration of erythromycin did not significantly alter systemic exposure to amlodipine (22% increase in AUC). Although the clinical relevance of this has not been revealed, pharmacokinetic changes may be more evident in elderly people. The possibility that strong cytochrome P3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) may increase plasma concentrations of amlodipine to levels higher than those seen with co-administration with diltiazem cannot be ruled out. Amlodipine should be administered with caution when administered in combination with cytochrome P3A4 inhibitors. However, no adverse reactions resulting from this drug interaction have been reported.
(5) CYP3A4 inducers: Co-administration with CYP3A4 inducers (e.g. rifampicin, St. John's wort (hypericum perforatum)) may change the plasma concentration of amlodipine. Therefore, blood pressure should be monitored and dose adjustments should be considered, especially during and after co-administration with strong CYP3A4 inducers.
8) Effect of amlodipine on other drugs
(1) Atorvastatin: There was no significant change in the steady-state pharmacokinetic parameters of atorvastatin when 80 mg of atorvastatin and multiple doses of 10 mg of amlodipine were coadministered.
(2) Digoxin: When amlodipine and digoxin were co-administered to healthy volunteers, there was no change in serum digoxin levels or renal clearance of digoxin.
(3) Ethanol (alcohol): There was no significant change in the pharmacokinetics of ethanol during single and repeated administration of 10 mg amlodipine.
(4) Warfarin: There was no effect on the warfarin-prothrombin reaction time when amlodipine and warfarin were administered together.
(5) Cyclosporine: In several studies in which cyclosporine and this drug were co-administered in kidney transplant patients, it was reported that the trough blood concentration of cyclosporine remained unchanged or increased by up to 40% when administered in combination with this drug.
(6) Tacrolimus: When coadministered with this drug, there is a risk of increased blood concentration of tacrolimus. Therefore, when administering this drug to patients treated with tacrolimus, the blood concentration of tacrolimus should be monitored and the dosage of tacrolimus should be appropriately adjusted to avoid tacrolimus toxicity.
(7) Simvastatin: Multiple-dose co-administration of 10 mg of amlodipine and 80 mg of simvastatin increased the exposure of simvastatin by approximately 77% compared to administration of simvastatin alone. In patients receiving amlodipine, the maximum daily dose of simvastatin is up to 20 mg.
○ Rosuvastatin
1) How other drugs affect rosuvastatin
In vitro and in vivo studies have shown that rosuvastatin does not interact clinically with cytochrome P450 (acting as a substrate, inhibitor or inducer).
Rosuvastatin is a substrate for some transporter proteins, such as the liver uptake drug transporter OATP1B1 and the efflux transporter BCRP. If this drug is used together with an inhibitor of this transporter protein, the blood concentration of rosuvastatin may increase, increasing the risk of myopathy (see table below).
※ <Effect of other drugs on rosuvastatin exposure (AUC) (based on published clinical results)>: See attached document.
Effects of other drugs
- Antacids: When rosuvastatin was co-administered with antacids containing aluminum hydroxide and magnesium hydroxide, the plasma concentration of rosuvastatin decreased by about 50%. However, this effect was alleviated when antacids were administered 2 hours after rosuvastatin. The clinical relevance of this interaction has not been studied.
- Fusidic acid: Interaction studies between rosuvastatin and fusidic acid have not been conducted. As with other statin drugs, muscle-related adverse reactions, including rhabdomyolysis, have been reported when rosuvastatin and fusidic acid were used together in post-marketing experience. Therefore, combined use of rosuvastatin and fusidic acid is not recommended. If possible, it is recommended to temporarily discontinue rosuvastatin administration, and if administration is unavoidable, close monitoring should be performed.
- Ticagrelor: Ticagrelor may affect the excretion of rosuvastatin through the kidneys, increasing the risk of rosuvastatin accumulation. In some cases, coadministration of ticagrelor and rosuvastatin resulted in decreased renal function, increased CPK levels, and rhabdomyolysis.
2) Effect of rosuvastatin on other drugs
- Warfarin: When used in combination with rosuvastatin, warfarin has no significant effect on pharmacokinetics. However, like other HMG-CoA reductase inhibitors, coadministration of rosuvastatin and warfarin may increase the INR compared to administration of warfarin alone. In patients receiving vitamin K antagonists (e.g. warfarin), INR monitoring is recommended when starting, discontinuing, or adjusting the dose of this drug.
- Cyclosporine: Co-administration of rosuvastatin and cyclosporine does not affect the blood concentration of cyclosporine.
- Fenofibrate/fibric acid derivatives: Pharmacokinetic interactions between fenofibrate and rosuvastatin were not observed, but pharmacokinetic interactions may occur. Gemfibrozil, fenofibrate, other fibrate-based drugs, and nicotinic acid in lipid-lowering doses (more than 1 g per day) can cause myopathy when administered alone, and therefore increase the risk of myopathy when administered in combination with HMG-CoA reductase inhibitors. When co-administering fibrate-type drugs, administration of 40 mg of rosuvastatin is contraindicated, and 5 mg should be administered as the initial dose.
- Oral contraceptives: When administered in combination with oral contraceptives, the AUC of ethinyl oestradiol and norgestrel increased by 26% and 34%, respectively. This increase in plasma concentration should be taken into consideration when selecting the dosage of oral contraceptives. Since there is no pharmacokinetic data for patients taking rosuvastatin and HRT together, a similar effect should not be ruled out. However, in clinical trials, the combination was administered frequently in women and the tolerability was excellent.
- Effects on other drugs: There was no clinically significant interaction with digoxin or ezetimibe.
6. Administration to pregnant and lactating women
The safety of this drug for pregnant and lactating women has not been established, so it should not be used by pregnant women, women who may be pregnant, or lactating women. Information on individual ingredients is as follows.
○ Amlodipine
1) The safety of amlodipine in pregnant women has not been established. Other than delayed and prolonged parturition in rats administered amlodipine at a dose equivalent to 50 times the maximum recommended dose for humans, no reproductive toxicity has been proven in animals. Therefore, administration to pregnant women is recommended only when there are no other safe alternative drugs and when the disease itself poses a significant risk to the mother and fetus. There was no effect on fertility in rats administered amlodipine.
2) The safety of amlodipine for lactating women has not been established. Therefore, it is recommended to discontinue breast-feeding while administering amlodipine. In human administration experience, it has been reported that amlodipine passes into human breast milk.
○ Rosuvastatin
The safety of rosuvastatin in pregnant and lactating women has not been established and should not be used during pregnancy or lactation.
Women of childbearing potential should use appropriate contraception. Because cholesterol and cholesterol biosynthesis products are essential for fetal development, the potential risks of inhibiting HMG-CoA reductase outweigh the benefits of treatment during pregnancy. There is evidence of limited reproductive toxicity in animal studies. If you become pregnant while using this medicine, you should stop taking it immediately. Rosuvastatin is passed into rat breast milk. There are no data on transfer to breast milk in humans.
7. Administration to children
The safety and effectiveness of this drug in children have not been established.
8. Administration to elderly people
Amlodipine is recommended to be administered at the usual dose. When amlodipine is administered at similar doses to elderly and young patients, the tolerability is equally good.
9. Treatment in case of overdose
There is no information about overdose with this drug. Information on overdose of each single drug is as follows.
○ Amlodipine
Current data indicate that severe overdose may result in reflex tachycardia along with excessive peripheral vasodilation. In addition, it has been reported that symptoms of systemic hypotension are severe and persist for a long time, leading to a state of shock or resulting in fatal shock. When Medicinal Carbon was administered immediately or up to 2 hours after administering 10 mg of amlodipine to healthy volunteers, the absorption of amlodipine was significantly reduced. In some cases, gastric lavage may be useful. Clinically serious hypotension caused by overdose of this drug requires active supportive treatment for the cardiovascular system, such as frequent monitoring of heart and respiratory function, maintaining the position of the limbs higher than the body, and ensuring sufficient circulating fluids such as blood and urine excretion. Unless there are special cases where the use of vasoconstrictors is contraindicated, vasoconstrictors may be useful in restoring vascular tone and blood pressure. Intravenous administration of calcium gluconate may be useful in reversing the effects of calcium channel inhibitors. Because amlodipine has a very high protein binding rate, hemodialysis is not helpful. Non-cardiogenic pulmonary edema has been rarely reported following amlodipine overdose. This may occur delayedly (24-48 hours after taking the dose) and may require ventilatory support. Early resuscitative measures to maintain perfusion and cardiac output (including fluid overload) may be precipitating factors.
○ Rosuvastatin
There is no special treatment in case of overdose. In case of overdose, symptomatic and supportive treatment should be administered. Liver function and CK levels should be monitored. Hemodialysis does not appear to help.
10. Precautions for storage and handling
1) Be careful to keep it out of reach of children.
2) Taking medicine out of its original container and storing it in another container may cause accidents due to misuse of the medicine or cause a decrease in the quality of the medicine, so keep it in the original container.
11. Information for experts
1) Pharmacological action
(1) Rosuvastatin: HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitor. This is a drug that inhibits HMG-CoA reductase, which plays a role in catalyzing the conversion of HMG-CoA to mevalonate in the initial rate control stage of cholesterol biosynthesis.
(2) Amlodipine: As a calcium channel blocker (CCB), it inhibits the influx of calcium ions into vascular smooth muscles and myocardial cells, thereby lowering blood pressure.
2) Pharmacokinetic information
(1) One biopharmaceutical test was conducted to compare the bioavailability of this drug (amlodipine/rosuvastatin) with the approved co-administration of 10 mg of amlodipine and 20 mg of rosuvastatin. A total of 36 healthy adults were administered a single dose of 10 mg of amlodipine and 20 mg of rosuvastatin on an empty stomach as a combination drug or an approved drug (2×2 crossover test). When the pharmacokinetic parameters were compared and evaluated by measuring the amlodipine and rosuvastatin concentrations in the blood, the 90% confidence intervals of the mean difference obtained by log-transforming the comparative evaluation item values (AUClast, Cmax) were all within the range of bioequivalence.
(2) One comparative pharmacokinetic study was conducted to evaluate the pharmacokinetic drug interaction between amlodipine and rosuvastatin. A total of 48 healthy adults participated and took 20 mg of rosuvastatin, 10 mg of amlodipine, or a combination of the two ingredients for 5 or 8 days (2-group, 2-stage, 1-sequence group trial). As a result of the test, there was no effect on the exposure of amlodipine in the presence of rosuvastatin, and the AUCτ,ss of rosuvastatin increased by about 1.2 times and the Cmax,ss by about 1.3 times in the presence of amlodipine.
(3) Although not a test conducted with this drug, rosuvastatin increased the median AUC and Cmax approximately two-fold in Asians (Japan, China, Philippines, Vietnam, Korea) compared to Caucasians. Demographic pharmacokinetic analysis showed no clinically meaningful pharmacokinetic differences between Caucasians and blacks.
3) Clinical trial information
The safety and effectiveness of this drug (rosuvastatin/amlodipine 20/10 mg) were evaluated in one multicenter, randomized, double-blind, parallel group trial using a single agent of each ingredient as a reference drug in patients with essential hypertension accompanied by dyslipidemia.
Before randomization, the test subjects were administered a placebo once a day during a 4-6 week therapeutic lifestyle correction period. After the therapeutic lifestyle correction period, 106 patients whose sitting systolic blood pressure and LDL-C met the drug administration criteria were randomized to test group (rosuvastatin/amlodipine 20/10mg), control group 1 (rosuvastatin 20mg), or control group 2 (amlodipine 10mg). They were assigned to receive clinical trial drugs for 8 weeks. Among these, safety was evaluated for 105 people who received the investigational drug, and effectiveness was evaluated for 104 people for whom primary efficacy endpoints were measured at least once. As co-primary efficacy endpoints, the change in msSBP of the test group compared to control group 1 (rosuvastatin administration group) and the LDL-C change rate (%) of the test group compared to control group 2 (amlodipine administration group) were evaluated.
When analysis of covariance (ANCOVA) was performed on the primary efficacy endpoints, LDL-C change rate (%) and msSBP change compared to baseline, with baseline values corrected as covariates, the LDL-C change rate and msSBP change in the test group were superior to the respective control groups. (p<0.0001)
Table. In a comparative study between this drug and each individual single agent in patients with essential hypertension accompanied by dyslipidemia, results at 8 weeks (FAS-LOCFa)
※ Table: Refer to attached document
4) Toxicity test information
(1) Repeated dose toxicity
A repeated-dose toxicity test was conducted in rats in which test substances (amlodipine/rosuvastatin) were orally administered for 13 weeks, and no new unknown toxicological changes were observed in each single ingredient.
(2) Reproductive and developmental toxicity
Although additional reproductive and developmental toxicity tests were not conducted for the development of combination drugs, the known reproductive and developmental toxicity for each single drug is as follows.
① Amlodipine: Other than delayed and prolonged parturition in rats administered amlodipine at a dose equivalent to 50 times the maximum recommended dose for humans, no reproductive toxicity has been proven in animals.
② Rosuvastatin: In prenatal and postnatal developmental tests in rats, reproductive toxicity was observed, including reduced litter size, reduced litter weight, and decreased survival of the next generation. This effect appeared when a dose equivalent to several times the therapeutic dose was administered systemically to the mother.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle
7. Period of use
36 months from date of manufacture
- Active ingredients:
Rosuvastatin calcium (EP) ······ 5.2mg (5mg as rosuvastatin)
Amlodipine besylate (EP) ······ 6.944mg (5mg as amlodipine)
- Additives: light anhydrous silicic acid, di-mannitol, microcrystalline cellulose, magnesium stearate, Opadry Orange (03B630006), sodium starch glycolate, pregelatinized starch, crospovidone, magnesium carbonate, povidone
2. Effectiveness
This drug is only used in patients who need to take two drugs (amlodipine and rosuvastatin) simultaneously.
○ Amlodipine
1. Myocardial ischemia caused by hypertension, fixed occlusion of the coronary artery (stable angina), or vasospasm and vasoconstriction of the coronary vascular system (atypical angina)
2. Patients with coronary heart disease recently confirmed by angiography and who do not have heart failure or cardiac output less than 40%
- Reduces the risk of hospitalization due to angina pectoris
- Reduced risk of coronary artery revascularization
○ Rosuvastatin
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb): As an adjunct to diet therapy if it cannot be controlled with diet and exercise
2. Adjuvant to diet or other lipid-lowering therapy (e.g. LDL apheresis) for homozygous familial hypercholesterolemia
3. Delays the progression of atherosclerosis by lowering total cholesterol and LDL-cholesterol to target levels in patients with hypercholesterolemia.
4. Dietary supplement for patients with primary dysbetalipoproteinemia (type III)
5. Reduced risk of cardiovascular disease: Patients with no clinical evidence of coronary heart disease, but men over 50 years of age and women over 60 years of age, high sensitive C-reactive protein (hsCRP) of 2 mg/L or more, and at least one additional cardiovascular disease risk factor (e.g. high blood pressure, low HDL-cholesterol level, smoking, or family history of premature coronary heart disease, etc.)
- Reduced risk of stroke
- Reduced risk of myocardial infarction
- Reduced risk of arterial revascularization
3. Dosage and dosage
This drug is administered only to adults, and the dosage should be individualized for each patient based on the effectiveness and tolerability of each component of amlodipine/rosuvastatin.
○ Amlodipine
Adults: Amlodipine is administered orally at 5 mg once a day, and the dose can be increased up to 10 mg per day depending on the patient's response. Increase or decrease appropriately depending on symptoms.
○ Rosuvastatin
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbeta-lipoproteinemia (type III), and homozygous familial hypercholesterolemia.
Patients before and while taking this drug should eat a standard cholesterol-lowering diet, and this should be continued during the treatment period. You can take this medication at any time of the day, regardless of meals. The initial dose is 5 milligrams once a day, and if further LDL-cholesterol level reduction is required, the maintenance dose can be adjusted. The maintenance dose is 10 milligrams once a day, and most patients are adjusted to this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more depending on the LDL-cholesterol level, treatment goals, and patient response, and the dose can be increased up to 20 milligrams per day.
2. Elderly: No dosage adjustment is necessary.
3. Patients with renal failure: For patients with mild to moderate renal failure, there is no need to adjust the dose. Do not administer to patients with severe renal failure. Particular caution should be exercised when administering 20 mg of this drug to patients with moderate renal failure.
4. Patients with liver failure: There was no increase in systemic exposure to rosuvastatin in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score exceeding 9. This drug is not administered to patients with active liver disease.
5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of doses of 40 milligrams is contraindicated.
6. Patients prone to myopathy: The recommended initial dose for patients prone to myopathy is 5 milligrams. In some of these patients, administration of rosuvastatin at a dose of 40 mg is contraindicated.
If a patient is taking amlodipine and rosuvastatin in combination, they can switch to this drug (a combination drug with the same content of each active ingredient) for convenience of administration.
4. Precautions for use
1. Do not administer to the following patients
1) Patients with hypersensitivity to the components of this drug or other dihydropyridine drugs
2) When administering this drug to pregnant women or women who may be pregnant, women of childbearing age who do not use an appropriate method of contraception, or lactating women or women of childbearing age, administer this drug only when informed of the high possibility of not becoming pregnant and the potential risk to the fetus.
3) Patients with severe liver dysfunction
4) Patients with active liver disease, including persistent serum transaminase elevations of unknown cause or serum transaminase elevations exceeding 3 times the upper limit of normal.
5) Patients with severe aortic stenosis
6) Shock patients
7) Patients with myopathy
8) Patients taking cyclosporine concurrently
9) Patients with severe renal failure (creatinine clearance (CLcr) <30mL/min)
10) Rosuvastatin administration at a dose of 40 mg is contraindicated in patients prone to myopathy/rhabdomyolysis. These factors are as follows.
- Moderate renal impairment (creatinine clearance < 60ml/min)
- Hypothyroidism
- If you have a history or family history of genetic muscle disease
- If there is a history of muscle toxicity to other HMG-CoA converting enzyme or fibrate drugs
- alcoholism
- Situations in which plasma concentrations may increase
- Asian patient
- Concomitant administration of fibrate-based drugs
2. Administer with caution to the following patients.
1) Patients with severe low blood pressure
2) Patients with renal failure requiring dialysis
3) Elderly people
4) Patients with severe muscle atony or ocular muscle atony (cases of recurrence when administered the same or different types of statin drugs have been reported).
5) Like other HMG-CoA reductase inhibitors, rosuvastatin should be administered with caution to patients who consume excessive alcohol or have a history of liver disease. It is recommended that liver enzyme tests be performed repeatedly as clinically necessary before and after starting treatment with this drug. Patients with hypercholesterolemia secondary to hypothyroidism or nephrotic syndrome must treat the causative disease before taking this drug.
6) Similar to other HMG-CoA reductase inhibitors, effects on skeletal muscle, such as myalgia and myopathy, and rarely rhabdomyolysis, have been reported in patients receiving rosuvastatin. Immune-mediated necrotizing myopathy has been reported in patients taking or discontinuing statins, including rosuvastatin. Immune-mediated myopathy is clinically characterized by weakened proximal muscles and increased CK (creatine kinase) in the blood, and the symptoms persist even after discontinuation of treatment.
· As with other HMG-CoA reductase inhibitors, the risks and benefits of treatment should be considered in the following patients with factors predisposing to myopathy/rhabdomyolysis, and clinical monitoring is recommended. Treatment should not be started if the CK (creatine kinase) value is significantly increased from the baseline level (more than 5 times the upper limit of normal) before treatment.
- Patients with renal impairment
- Hypothyroidism
- If you have a history or family history of genetic muscle disease
- If there is a history of muscle toxicity to other HMG-CoA reductase inhibitors or fibrates.
- alcohol abuse
- Seniors over 70 years old
- Situations in which plasma concentrations may increase
- Concomitant administration of fibrate-based drugs
· During treatment, unexplained muscle pain, muscle weakness or cramps should be reported immediately, especially if associated with malaise or fever. In these patients, the CK level should be measured, and if the CK level is significantly elevated (more than 5 times the upper limit of normal) or if the muscle symptoms are severe and cause daily discomfort even if the CK level increases below 5 times the upper limit of normal, administration of this drug should be discontinued. Once symptoms resolve and CK levels return to normal, consideration should be given to restarting rosuvastatin or another HMG-CoA reductase inhibitor at the lowest dose with close monitoring. Routine monitoring of CK levels is not necessary in asymptomatic patients.
· Because it may make interpretation of the measurement results difficult, do not measure the CK value after intense exercise or when there are other causes that may increase the CK value. If the CK value increases significantly from baseline (more than 5 times the upper limit of normal), a confirmatory test should be performed within 5 to 7 days. Even when repeating the test, this drug should not be administered if the baseline CK value increases more than 5 times the upper limit of normal.
7) This drug should be discontinued in acute severe conditions that suggest worsening of myopathy or renal failure secondary to rhabdomyolysis (e.g., sepsis, hypotension, major surgery, wounds, severe metabolic/endocrine/electrolyte diseases, uncontrolled epileptic seizures).
8) In clinical trials, there was no evidence of increased effect on skeletal muscle in the small number of patients who received rosuvastatin alone and in combination with other drugs. However, in the case of other HMG-CoA reductase inhibitors, the frequency of myositis and myopathy increased in patients receiving concurrent treatment with fibric acid derivatives (including gemfibrozil), cyclosporine, nicotinic acid, azole antifungals, protease inhibitors, and macrolide antibiotics. Gemfibrozil increases the risk of myopathy when combined with HMG-CoA reductase inhibitors. Therefore, the combined use of this drug and gemfibrozil is not recommended. When administering this drug in combination with fibrates or niacin, the benefits and risks should be carefully evaluated. A dose of 40 milligrams of rosuvastatin is contraindicated when coadministered with fibrate-based drugs.
9) In patients taking high doses of rosuvastatin, especially 40 mg, proteinuria, mostly of tubular origin, detected by dipstick test was observed. This is usually transient and is not a predictor of acute or progressive renal failure. Renal function tests should be considered during the follow-up period for patients receiving rosuvastatin 40 mg.
10) According to the pharmacokinetics test of rosuvastatin, increased systemic exposure (median AUC and Cmax approximately 2-fold increase) was found in Asians compared to Caucasians, so this should be taken into consideration when determining dosage for Asians.
11) This medicine 5/5 and 20/5mg contain Yellow No. 5 (Sunset Yellow FCF), so administer with caution to patients who are hypersensitive to this ingredient or have a history of allergy.
3. Adverse reactions
○ Information collected from this medicine (combined medicine)
1) Clinical trials
The safety of this drug was evaluated in a clinical trial in which 105 patients with essential hypertension and dyslipidemia were administered this drug (rosuvastatin/amlodipine 20/10 mg) or rosuvastatin 20 mg or amlodipine 10 mg once daily for 8 weeks.
The adverse reactions reported in this clinical trial, regardless of causal relationship, are listed in Table 1.
※ <Table 1> Adverse reactions: See attached document
Among these, adverse drug reactions for which a causal relationship with the drug could not be ruled out were peripheral edema in 5.71% (2 people) of the drug-treated group, dizziness 2.78% (1 person) in the rosuvastatin-treated group, and headache 2.94% (1 person) in the amlodipine-treated group.
2) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 654 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 26.30% (172/654 people, 237 cases) regardless of causal relationship.
Among these, no serious adverse drug reactions for which a causal relationship cannot be ruled out were reported, and unexpected adverse drug reactions are listed in the table below according to their frequency of occurrence.
※ Table: Refer to attached document
○ Information collected from amlodipine
1) Amlodipine is well tolerated. In placebo-controlled clinical trials in patients with hypertension and angina, the most common adverse reactions were as follows:
Vascular disorders: flushing
Whole body: fatigue, swelling
Cardiovascular system: palpitations
Central and peripheral nervous system: dizziness, headache, drowsiness
Digestive system: abdominal pain, nausea
No clinically significant laboratory abnormalities related to this drug were observed in clinical trials.
2) Adverse reactions observed with relatively low frequency after marketing are as follows:
Systemic: weakness, malaise, pain, weight gain/loss
Vascular disorders: hypotension, vasculitis
Nervous system: hypertonia, hypoesthesia/dysesthesias, peripheral neuropathy, syncope, dysgeusia, tremor, extrapyramidal disorder.
Reproductive system: erectile dysfunction, gynecomastia
Digestive system: Changes in bowel habits, dry mouth, indigestion (gastritis), gingival thickening, pancreatitis, vomiting.
Metabolism/Nutrition: Hyperglycemia
Musculoskeletal system: joint pain, back pain, muscle cramps, muscle pain
Blood and lymphatic system disorders: leukopenia, thrombocytopenia
Mental: Insomnia, mood swings
Respiratory disorders: cough, dyspnea, rhinitis
Skin/Appendixes: Hair loss, hyperhidrosis, purpura, skin discoloration, urticaria, toxic epidermal necrolysis
Sensory system: sound in ears, visual abnormality
Urinary system: increased urination frequency, urinary disorders, enuresis
Hepatobiliary system: Hepatitis, jaundice, and elevated liver enzyme levels were reported very rarely, and most of these were related to cholestasis. Some cases that were severe enough to require hospitalization were reported to be related to the use of amlodipine, but in most cases, the causal relationship with amlodipine is unclear.
Rarely, allergic reactions including pruritus, rash, angioedema, and erythema multiforme have been reported.
3) As with other calcium channel inhibitors, the following adverse reactions were rarely reported, but it was not possible to distinguish whether they were caused by the underlying disease or the drug: myocardial infarction, arrhythmia (including bradycardia, ventricular tachycardia, and atrial fibrillation), and chest pain.
4) Other adverse reactions as follows were observed.
Cardiovascular system: Occasionally, a drop in blood pressure, sinoatrial or atrioventricular block, and rarely abdominal discomfort may occur.
Digestive system: Occasionally, abdominal pain, diarrhea, loose stools, and constipation may occur.
Skin: In rare cases, redness of the skin and petechial-papular rash may occur.
Others: Occasionally, headache, hot flashes, decreased glucose tolerance, and weakness may occur.
○ Information collected from rosuvastatin
1) Reported adverse reactions were generally mild and transient. Less than 4% of patients in the rosuvastatin treatment group discontinued the study due to adverse reactions.
The frequency of adverse reactions was classified as follows:
Common (>1/100, <1/10);
Uncommon (>1/1,000, <1/100);
Rare (>1/10,000, <1/1,000);
Very rare (<1/10,000).
Not known (cannot be estimated from available data)
※ Table: Refer to attached document
As with other HMG-CoA reductase inhibitors, adverse reactions tended to increase as the dose increased.
2) Effect on kidneys: Proteinuria, mostly of tubular origin, detected by dipstick test, was observed. The phenomenon of conversion of urine protein from negative or very small amounts to ++ or higher occurred in less than 1% of cases at 10 or 20 milligrams and in about 3% of cases at 40 milligrams. A slight increase in urine protein from negative or very small amounts to + was also observed at the 20 mg dose. Proteinuria decreased or disappeared spontaneously during treatment in most cases and is not a predictor of acute or progressive renal failure. Hematuria was observed in patients and clinical trial data administered rosuvastatin, but the frequency of occurrence was low.
3) Effects on the musculoskeletal system: Effects on the musculoskeletal system with or without acute renal failure (e.g., myalgia, myopathy (including myositis), rarely rhabdomyolysis, etc.) have been reported in patients treated with all doses of rosuvastatin (especially doses above 20 mg). In the patient group receiving rosuvastatin, creatinine kinase (CK) levels increased in a dose-dependent manner. In most cases, it was mild, asymptomatic, and transient. If creatinine kinase (CK) levels increase significantly (more than 5 times the upper normal limit), treatment should be temporarily discontinued.
4) Effects on the liver: As with other HMG-CoA reductase inhibitors, transaminase levels increased in a dose-dependent manner in a small number of patients receiving rosuvastatin. In most cases, it was mild, asymptomatic, and transient.
5) Overseas post-marketing experience
In addition to the above adverse reactions, the following adverse reactions were reported during post-marketing surveillance.
- Nervous system: Very rare polyneuropathy, amnesia, peripheral neuropathy (frequency unknown)
- Respiratory system and chest: cough, difficulty breathing (frequency unknown)
- Gastrointestinal system: Diarrhea (frequency unknown)
- Hematological disorders: Thrombocytopenia (frequency unknown)
- Hepatobiliary system: very rare, jaundice, hepatitis, rarely increased transaminases
- Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome (frequency unknown), drug reaction syndrome with increased eosinophils and systemic symptoms (DRESS) (frequency unknown)
- Musculoskeletal system: Rarely lupus-like syndrome, muscle rupture, very rarely arthralgia, immune-mediated necrotizing myopathy (frequency unknown)
- Kidney: Very rare hematuria
- Other: Edema (frequency unknown)
The following adverse reactions have been reported in relation to some statin drugs.
- Mental nervous system: depression, sleep disorders (including insomnia and nightmares) (frequency unknown)
- Respiratory system: Exceptional cases such as interstitial lung disease, especially during long-term administration
- Urogenital system: sexual dysfunction, gynecomastia (frequency unknown)
- Hepatobiliary system: Fatal and non-fatal liver failure
There have been rare reports of post-marketing cognitive impairment associated with statin use. (e.g. memory loss, forgetfulness, amnesia, memory impairment, confusion) Such cognitive impairment has been reported with all statin drugs. These reports are generally not serious and reversible after discontinuation of drug use, but there is variation in the time of symptom onset (1 day to several years) and symptom improvement (median 3 weeks). The induction or worsening of severe muscle atony or ocular muscle atony has been reported with the administration of statin drugs.
6) Domestic post-marketing survey results
As a result of a use result survey conducted on 3,081 people over 6 years for re-examination in Korea, the incidence of adverse events regardless of causal relationship was 10.06% (310 people, 415 cases), mainly headache 0.78% (24 people, 24 cases), dizziness 0.75% (23 people, 23 cases), and ALT increase 0.58% (18 people, 18 cases). 18 cases), chest pain, cough, and muscle pain were reported in 0.49% (15 people, 15 cases) respectively. Of these, 2.92% (90 people, 106 cases) of adverse drug reactions for which a causal relationship with rosuvastatin could not be ruled out.
The most reported adverse drug reactions were ALT increase at 0.55% (17 people, 17 cases), muscle pain at 0.42% (13 people, 13 cases), headache at 0.39% (12 people, 12 cases), CK increase at 0.29% (9 people, 9 cases), dizziness at 0.26% (8 people, 8 cases), constipation, and AST increase. 0.16% (5 people, 5 cases), asthenia and joint pain each at 0.13% (4 people, 4 cases), fatigue and numbness at 0.10% each (3 people, 3 cases), paresthesia, chest discomfort, nausea, abdominal pain, diarrhea, loss of appetite, abdominal distension, itching, liver function test abnormalities at 0.06% each (2 people, 2 cases), syncope, systemic pain, Muscle cramps, gout, and erectile dysfunction each occurred in 0.03% (1 person, 1 case). Among these, muscle pain and joint pain in one patient were serious adverse drug reactions, and unexpected adverse drug reactions that did not occur before marketing included joint pain in 0.13% (4 patients, 4 cases), fatigue and numbness in 0.10% each (3 patients, 3 cases), paresthesia, chest discomfort, loss of appetite, abdominal distension, and liver function test abnormalities in 0.06% each (2 patients, 2 cases), syncope, and Systemic pain, muscle spasms, gout, and erectile dysfunction occurred in 0.03% (1 person, 1 case) each, and one case of joint pain was reported as a serious and unexpected adverse drug reaction.
There were 98 adverse events voluntarily reported during the re-examination period, of which 2 cases of acute renal failure and 1 case each of oliguria, thrombocytopenia, and increased blood creatinine were reported as serious and unexpected adverse drug reactions.
4. General precautions
○ Amlodipine
1) Administration to heart failure patients: In the long-term, placebo-controlled trial (PRAISE-2) of amlodipine in New York Heart Association (NYHA) class III and IV heart failure patients without ischemic etiology, amlodipine was associated with an increase in reports of pulmonary edema despite no significant difference in the worsening rate of heart failure compared to placebo.
2) Administration to patients with liver dysfunction: Like all calcium antagonists, the half-life of amlodipine is prolonged in patients with liver dysfunction, and the recommended dosage for these patients has not been established. Therefore, administer with caution to these patients.
3) Because the plasma concentration half-life is long, a gradual blood pressure lowering effect appears even after discontinuation of administration. Therefore, when administering other antihypertensive drugs after discontinuation of administration, pay attention to the dosage and administration interval and administer carefully while observing the patient's condition.
4) Since the effect appears slowly, the effect cannot be expected for unstable angina pectoris that requires emergency treatment.
5) Effects on driving and using machines
Based on clinical experience with amlodipine, it does not appear to impair the ability to drive or use machines.
○ Rosuvastatin
1) Interstitial lung disease: Unusual cases such as interstitial lung disease have been reported with some statin drugs, especially during long-term administration. Presenting symptoms may include difficulty breathing, cough without phlegm, and general deterioration in health (fatigue, weight loss, and fever). If a patient is suspected of developing interstitial lung disease, statin drug treatment should be discontinued.
2) Post-marketing cases of fatal and non-fatal liver failure have been rarely reported in patients taking statin drugs, including rosuvastatin. If severe liver damage and/or hyperbilirubinemia or jaundice with clinical symptoms occurs while taking this drug, treatment should be discontinued immediately. Do not re-administer this drug if no other etiology is found.
3) An increase in HbA1c and fasting blood sugar levels was reported when administering HMG-CoA reductase inhibitors, including rosuvastatin.
4) Diabetes: Some evidence suggests that hyperglycemia, which requires appropriate diabetes treatment, may occur in some patients at high risk of developing diabetes in the future. However, the vascular risk reduction effect of statins exceeds these risks and therefore cannot be a reason to discontinue statin treatment. Patients at risk (fasting blood sugar 5.6-6.9 mmol/L, BMI > 30kg/m2, elevated triglyceride level, hypertension) should undergo clinical and laboratory monitoring according to treatment guidelines. In the JUPITER study, the total incidence of diabetes reported in patients with fasting blood sugar levels of 5.6 to 6.9 mmol/L was 2.8% in the rosuvastatin group and 2.3% in the placebo group.
5) Genetic polymorphism: Compared to SLCO1B1 c.521TT and ABCG2 c.421CC, genotypes of SLCO1B1 (OATP1B1) c.521CC or ABCG2 (BCRP) c.421AA were reported to be associated with increased exposure (AUC) of rosuvastatin. Although the safety and effectiveness of this drug according to genetic polymorphisms have not been established, the dose needs to be adjusted according to the patient's treatment response and tolerance.
6) Severe skin adverse reactions: Severe skin adverse reactions that can be life-threatening or fatal, such as Stevens-Johnson syndrome (SJS), increased eosinophilia, and drug reaction syndrome with systemic symptoms (DRESS), have been reported with rosuvastatin. When prescribing, patients should be counseled and closely monitored for symptoms and signs of severe skin reactions. If symptoms and signs suggestive of these skin reactions occur, this medication should be discontinued immediately and alternative treatment options should be considered.
If a patient develops a severe reaction such as Stevens-Johnson syndrome or drug reaction syndrome with eosinophilia and systemic symptoms due to the use of this drug, treatment with this drug should not be resumed at any time.
7) Severe muscle asthenia and ocular muscle atony: Rarely, statin drugs may cause or worsen severe muscle asthenia or ocular muscle atony. This drug should be used with caution in patients with these conditions. Administration should be discontinued if severe muscle atony or ocular muscle atony occurs or worsens.
5. Interaction
As a result of a drug interaction test conducted by administering 20 mg of rosuvastatin and 10 mg of amlodipine to healthy volunteers, the Cmax,ss of rosuvastatin increased by about 1.3 times and the AUCτ,ss increased by about 1.2 times.
Studies on drug interactions between other drugs and the rosuvastatin/amlodipine combination were not conducted, but studies on the individual drugs amlodipine and rosuvastatin were conducted as follows.
○ Amlodipine
1) Amlodipine is safe when used in combination with thiazide diuretics, alpha-blockers, beta-blockers, ACE inhibitors, long-acting nitrate agents, sublingual nitroglycerin tablets, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic agents.
2) Laboratory data using human plasma show that amlodipine does not affect the protein binding of digoxin, phenytoin, warfarin, and indomethacin.
3) Grapefruit juice: A single co-administration of 240 mL of grapefruit juice and 10 mg of amlodipine in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine. In this study, the impact of genetic polymorphisms in CYP3A4, the main metabolic pathway for amlodipine, was not evaluated. Therefore, co-administration of amlodipine with grapefruit or grapefruit juice may increase the blood pressure lowering effect in some patients due to increased bioavailability, so co-administration is not recommended.
4) Dantrolene (injection): In animal experiments where verapamil and dantrolene were administered through IV, fatal ventricular spasms were consistently observed. Simultaneous administration of amlodipine and dantrolene should be avoided.
5) Baclofen: As it increases the blood pressure lowering effect, administer with caution regarding blood pressure and dosage if necessary.
6) Clarithromycin: Clarithromycin is a cytochrome P3A4 inhibitor. The risk of hypotension is increased when clarithromycin is coadministered with this drug. It is recommended that patients be carefully observed when coadministering this drug and clarithromycin.
7) How other drugs affect amlodipine
(1) Cimetidine: When administered in combination with amlodipine, there was no effect on the pharmacokinetics of amlodipine.
(2) Aluminum/magnesium (antacid): When aluminum/magnesium antacid was coadministered with a single dose of amlodipine, there was no significant effect on the pharmacokinetics of amlodipine.
(3) Sildenafil: Administration of a single dose of 100 mg of sildenafil to patients with primary hypertension did not affect the pharmacokinetic parameters of amlodipine. When amlodipine and sildenafil are administered together, each drug exerts its own blood pressure lowering effect independently.
(4) Cytochrome P3A4 inhibitor: In elderly (69 to 87 years old) hypertensive patients, coadministration of 180 mg of diltiazem and 5 mg of amlodipine per day increased the systemic exposure of amlodipine by 57%. In healthy volunteers (18 to 43 years of age) co-administration of erythromycin did not significantly alter systemic exposure to amlodipine (22% increase in AUC). Although the clinical relevance of this has not been revealed, pharmacokinetic changes may be more evident in elderly people. The possibility that strong cytochrome P3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) may increase plasma concentrations of amlodipine to levels higher than those seen with co-administration with diltiazem cannot be ruled out. Amlodipine should be administered with caution when administered in combination with cytochrome P3A4 inhibitors. However, no adverse reactions resulting from this drug interaction have been reported.
(5) CYP3A4 inducers: Co-administration with CYP3A4 inducers (e.g. rifampicin, St. John's wort (hypericum perforatum)) may change the plasma concentration of amlodipine. Therefore, blood pressure should be monitored and dose adjustments should be considered, especially during and after co-administration with strong CYP3A4 inducers.
8) Effect of amlodipine on other drugs
(1) Atorvastatin: There was no significant change in the steady-state pharmacokinetic parameters of atorvastatin when 80 mg of atorvastatin and multiple doses of 10 mg of amlodipine were coadministered.
(2) Digoxin: When amlodipine and digoxin were co-administered to healthy volunteers, there was no change in serum digoxin levels or renal clearance of digoxin.
(3) Ethanol (alcohol): There was no significant change in the pharmacokinetics of ethanol during single and repeated administration of 10 mg amlodipine.
(4) Warfarin: There was no effect on the warfarin-prothrombin reaction time when amlodipine and warfarin were administered together.
(5) Cyclosporine: In several studies in which cyclosporine and this drug were co-administered in kidney transplant patients, it was reported that the trough blood concentration of cyclosporine remained unchanged or increased by up to 40% when administered in combination with this drug.
(6) Tacrolimus: When coadministered with this drug, there is a risk of increased blood concentration of tacrolimus. Therefore, when administering this drug to patients treated with tacrolimus, the blood concentration of tacrolimus should be monitored and the dosage of tacrolimus should be appropriately adjusted to avoid tacrolimus toxicity.
(7) Simvastatin: Multiple-dose co-administration of 10 mg of amlodipine and 80 mg of simvastatin increased the exposure of simvastatin by approximately 77% compared to administration of simvastatin alone. In patients receiving amlodipine, the maximum daily dose of simvastatin is up to 20 mg.
○ Rosuvastatin
1) How other drugs affect rosuvastatin
In vitro and in vivo studies have shown that rosuvastatin does not interact clinically with cytochrome P450 (acting as a substrate, inhibitor or inducer).
Rosuvastatin is a substrate for some transporter proteins, such as the liver uptake drug transporter OATP1B1 and the efflux transporter BCRP. If this drug is used together with an inhibitor of this transporter protein, the blood concentration of rosuvastatin may increase, increasing the risk of myopathy (see table below).
※ <Effect of other drugs on rosuvastatin exposure (AUC) (based on published clinical results)>: See attached document.
Effects of other drugs
- Antacids: When rosuvastatin was co-administered with antacids containing aluminum hydroxide and magnesium hydroxide, the plasma concentration of rosuvastatin decreased by about 50%. However, this effect was alleviated when antacids were administered 2 hours after rosuvastatin. The clinical relevance of this interaction has not been studied.
- Fusidic acid: Interaction studies between rosuvastatin and fusidic acid have not been conducted. As with other statin drugs, muscle-related adverse reactions, including rhabdomyolysis, have been reported when rosuvastatin and fusidic acid were used together in post-marketing experience. Therefore, combined use of rosuvastatin and fusidic acid is not recommended. If possible, it is recommended to temporarily discontinue rosuvastatin administration, and if administration is unavoidable, close monitoring should be performed.
- Ticagrelor: Ticagrelor may affect the excretion of rosuvastatin through the kidneys, increasing the risk of rosuvastatin accumulation. In some cases, coadministration of ticagrelor and rosuvastatin resulted in decreased renal function, increased CPK levels, and rhabdomyolysis.
2) Effect of rosuvastatin on other drugs
- Warfarin: When used in combination with rosuvastatin, warfarin has no significant effect on pharmacokinetics. However, like other HMG-CoA reductase inhibitors, coadministration of rosuvastatin and warfarin may increase the INR compared to administration of warfarin alone. In patients receiving vitamin K antagonists (e.g. warfarin), INR monitoring is recommended when starting, discontinuing, or adjusting the dose of this drug.
- Cyclosporine: Co-administration of rosuvastatin and cyclosporine does not affect the blood concentration of cyclosporine.
- Fenofibrate/fibric acid derivatives: Pharmacokinetic interactions between fenofibrate and rosuvastatin were not observed, but pharmacokinetic interactions may occur. Gemfibrozil, fenofibrate, other fibrate-based drugs, and nicotinic acid in lipid-lowering doses (more than 1 g per day) can cause myopathy when administered alone, and therefore increase the risk of myopathy when administered in combination with HMG-CoA reductase inhibitors. When co-administering fibrate-type drugs, administration of 40 mg of rosuvastatin is contraindicated, and 5 mg should be administered as the initial dose.
- Oral contraceptives: When administered in combination with oral contraceptives, the AUC of ethinyl oestradiol and norgestrel increased by 26% and 34%, respectively. This increase in plasma concentration should be taken into consideration when selecting the dosage of oral contraceptives. Since there is no pharmacokinetic data for patients taking rosuvastatin and HRT together, a similar effect should not be ruled out. However, in clinical trials, the combination was administered frequently in women and the tolerability was excellent.
- Effects on other drugs: There was no clinically significant interaction with digoxin or ezetimibe.
6. Administration to pregnant and lactating women
The safety of this drug for pregnant and lactating women has not been established, so it should not be used by pregnant women, women who may be pregnant, or lactating women. Information on individual ingredients is as follows.
○ Amlodipine
1) The safety of amlodipine in pregnant women has not been established. Other than delayed and prolonged parturition in rats administered amlodipine at a dose equivalent to 50 times the maximum recommended dose for humans, no reproductive toxicity has been proven in animals. Therefore, administration to pregnant women is recommended only when there are no other safe alternative drugs and when the disease itself poses a significant risk to the mother and fetus. There was no effect on fertility in rats administered amlodipine.
2) The safety of amlodipine for lactating women has not been established. Therefore, it is recommended to discontinue breast-feeding while administering amlodipine. In human administration experience, it has been reported that amlodipine passes into human breast milk.
○ Rosuvastatin
The safety of rosuvastatin in pregnant and lactating women has not been established and should not be used during pregnancy or lactation.
Women of childbearing potential should use appropriate contraception. Because cholesterol and cholesterol biosynthesis products are essential for fetal development, the potential risks of inhibiting HMG-CoA reductase outweigh the benefits of treatment during pregnancy. There is evidence of limited reproductive toxicity in animal studies. If you become pregnant while using this medicine, you should stop taking it immediately. Rosuvastatin is passed into rat breast milk. There are no data on transfer to breast milk in humans.
7. Administration to children
The safety and effectiveness of this drug in children have not been established.
8. Administration to elderly people
Amlodipine is recommended to be administered at the usual dose. When amlodipine is administered at similar doses to elderly and young patients, the tolerability is equally good.
9. Treatment in case of overdose
There is no information about overdose with this drug. Information on overdose of each single drug is as follows.
○ Amlodipine
Current data indicate that severe overdose may result in reflex tachycardia along with excessive peripheral vasodilation. In addition, it has been reported that symptoms of systemic hypotension are severe and persist for a long time, leading to a state of shock or resulting in fatal shock. When Medicinal Carbon was administered immediately or up to 2 hours after administering 10 mg of amlodipine to healthy volunteers, the absorption of amlodipine was significantly reduced. In some cases, gastric lavage may be useful. Clinically serious hypotension caused by overdose of this drug requires active supportive treatment for the cardiovascular system, such as frequent monitoring of heart and respiratory function, maintaining the position of the limbs higher than the body, and ensuring sufficient circulating fluids such as blood and urine excretion. Unless there are special cases where the use of vasoconstrictors is contraindicated, vasoconstrictors may be useful in restoring vascular tone and blood pressure. Intravenous administration of calcium gluconate may be useful in reversing the effects of calcium channel inhibitors. Because amlodipine has a very high protein binding rate, hemodialysis is not helpful. Non-cardiogenic pulmonary edema has been rarely reported following amlodipine overdose. This may occur delayedly (24-48 hours after taking the dose) and may require ventilatory support. Early resuscitative measures to maintain perfusion and cardiac output (including fluid overload) may be precipitating factors.
○ Rosuvastatin
There is no special treatment in case of overdose. In case of overdose, symptomatic and supportive treatment should be administered. Liver function and CK levels should be monitored. Hemodialysis does not appear to help.
10. Precautions for storage and handling
1) Be careful to keep it out of reach of children.
2) Taking medicine out of its original container and storing it in another container may cause accidents due to misuse of the medicine or cause a decrease in the quality of the medicine, so keep it in the original container.
11. Information for experts
1) Pharmacological action
(1) Rosuvastatin: HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitor. This is a drug that inhibits HMG-CoA reductase, which plays a role in catalyzing the conversion of HMG-CoA to mevalonate in the initial rate control stage of cholesterol biosynthesis.
(2) Amlodipine: As a calcium channel blocker (CCB), it inhibits the influx of calcium ions into vascular smooth muscles and myocardial cells, thereby lowering blood pressure.
2) Pharmacokinetic information
(1) One biopharmaceutical test was conducted to compare the bioavailability of this drug (amlodipine/rosuvastatin) with the approved co-administration of 10 mg of amlodipine and 20 mg of rosuvastatin. A total of 36 healthy adults were administered a single dose of 10 mg of amlodipine and 20 mg of rosuvastatin on an empty stomach as a combination drug or an approved drug (2×2 crossover test). When the pharmacokinetic parameters were compared and evaluated by measuring the amlodipine and rosuvastatin concentrations in the blood, the 90% confidence intervals of the mean difference obtained by log-transforming the comparative evaluation item values (AUClast, Cmax) were all within the range of bioequivalence.
(2) One comparative pharmacokinetic study was conducted to evaluate the pharmacokinetic drug interaction between amlodipine and rosuvastatin. A total of 48 healthy adults participated and took 20 mg of rosuvastatin, 10 mg of amlodipine, or a combination of the two ingredients for 5 or 8 days (2-group, 2-stage, 1-sequence group trial). As a result of the test, there was no effect on the exposure of amlodipine in the presence of rosuvastatin, and the AUCτ,ss of rosuvastatin increased by about 1.2 times and the Cmax,ss by about 1.3 times in the presence of amlodipine.
(3) Although not a test conducted with this drug, rosuvastatin increased the median AUC and Cmax approximately two-fold in Asians (Japan, China, Philippines, Vietnam, Korea) compared to Caucasians. Demographic pharmacokinetic analysis showed no clinically meaningful pharmacokinetic differences between Caucasians and blacks.
3) Clinical trial information
The safety and effectiveness of this drug (rosuvastatin/amlodipine 20/10 mg) were evaluated in one multicenter, randomized, double-blind, parallel group trial using a single agent of each ingredient as a reference drug in patients with essential hypertension accompanied by dyslipidemia.
Before randomization, the test subjects were administered a placebo once a day during a 4-6 week therapeutic lifestyle correction period. After the therapeutic lifestyle correction period, 106 patients whose sitting systolic blood pressure and LDL-C met the drug administration criteria were randomized to test group (rosuvastatin/amlodipine 20/10mg), control group 1 (rosuvastatin 20mg), or control group 2 (amlodipine 10mg). They were assigned to receive clinical trial drugs for 8 weeks. Among these, safety was evaluated for 105 people who received the investigational drug, and effectiveness was evaluated for 104 people for whom primary efficacy endpoints were measured at least once. As co-primary efficacy endpoints, the change in msSBP of the test group compared to control group 1 (rosuvastatin administration group) and the LDL-C change rate (%) of the test group compared to control group 2 (amlodipine administration group) were evaluated.
When analysis of covariance (ANCOVA) was performed on the primary efficacy endpoints, LDL-C change rate (%) and msSBP change compared to baseline, with baseline values corrected as covariates, the LDL-C change rate and msSBP change in the test group were superior to the respective control groups. (p<0.0001)
Table. In a comparative study between this drug and each individual single agent in patients with essential hypertension accompanied by dyslipidemia, results at 8 weeks (FAS-LOCFa)
※ Table: Refer to attached document
4) Toxicity test information
(1) Repeated dose toxicity
A repeated-dose toxicity test was conducted in rats in which test substances (amlodipine/rosuvastatin) were orally administered for 13 weeks, and no new unknown toxicological changes were observed in each single ingredient.
(2) Reproductive and developmental toxicity
Although additional reproductive and developmental toxicity tests were not conducted for the development of combination drugs, the known reproductive and developmental toxicity for each single drug is as follows.
① Amlodipine: Other than delayed and prolonged parturition in rats administered amlodipine at a dose equivalent to 50 times the maximum recommended dose for humans, no reproductive toxicity has been proven in animals.
② Rosuvastatin: In prenatal and postnatal developmental tests in rats, reproductive toxicity was observed, including reduced litter size, reduced litter weight, and decreased survival of the next generation. This effect appeared when a dose equivalent to several times the therapeutic dose was administered systemically to the mother.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle
7. Period of use
36 months from date of manufacture
Product Updates
Total 1items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 1 | Rotodipin Tab. 5/5mg | Precautions for use | 2026.04.07 | PDF202500591_Rotodipine tablet 5/5mg_Precautions for use (draft).pdf |